Subscribe: MedWorm: Benign Prostatic Hyperplasia
http://www.medworm.com/rss/medicalfeeds/conditions/Benign-Prostatic-Hyperplasia.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
benign prostatic  benign  bph  health  hyperplasia  medical  prostate  prostatic hyperplasia  prostatic  source  treatment 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Benign Prostatic Hyperplasia

MedWorm: Benign Prostatic Hyperplasia News



MedWorm.com provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Benign Prostatic Hyperplasia



Last Build Date: Thu, 08 Feb 2018 03:28:12 +0100

 



Zenflow raises $31m in Series A

Wed, 07 Feb 2018 19:21:06 +0100

Urology medical device maker Zenflow said today it closed a $31.4 million Series A round of financing to support the development of minimally invasive devices designed to treat obstructive urinary symptoms related to benign prostatic hyperplasia. The round was led by Invus Opportunities, F-Prime Capital Partners and Medical Technology Venture Partners and was joined by other new and existing investors, the San Francisco-based company said. Zenflow said it has also received grant funding from the National Institutes of Health and the National Science Foundation. The company’s first product is the Spring System device, which is designed to deliver a low-profile superelastic implant into the prostatic urethra. The system is intended to allow for a simple, physician-led procedure to reli...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




NxThera touts 3-year Rez ūm trial results

Thu, 04 Jan 2018 20:21:48 +0100

NxThera today released three-year results from a trial of its Rezūm convective water vapor wave energy system, touting effective and durable relief from lower urinary tract symptoms for patients with benign prostatic hyperplasia. The trial was co-authored by co-principal investigators Dr. Kevin McVary of Southern Illinois University School of Medicine and Dr. Claus Roehrborn of the University of Texas Southwestern Medical Center, and results were published in the January 2018 issue of the journal Urology. “Rezūm warrants consideration as a first-line treatment for BPH due to the durability of LUTS relief out to three years, along with its exceptional safety profile and no reported occurrences of erectile dysfunction. Additionally, Rezūm is a highly cost-effective solution for the...



Butterfly Medical wins CE Mark for in-office benign prostate hyperplasia device

Tue, 28 Nov 2017 16:07:16 +0100

Medical device developer Butterfly Medical said today it won CE Mark approval in the European Union for its device designed for the in-office treatment of benign prostate hyperplasia. The Israel-based company’s device is designed to dilate the prostatic urethra without any surgical incisions or prostate tissue removal. The device then secures tightly to the prostate tissue to prevent migration to move the lobes of the prostate out of the way and improve urine flow. “We are proud to bring a simple, non-surgical treatment option to the millions of men worldwide afflicted by BPH. With our Butterfly Medical device, they are able to receive treatment quickly and easily in their physician’s office. With market acceptance for our medical approach already demonstrated, our closest ...



Prostate problem? Take 2 nuts

Thu, 19 Oct 2017 17:24:48 +0100

By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life. Traditional doctors give you two choices. Go under the knife or you take Big Pharma’s drugs. Either way, you have a good chance of ending up with your manhood on the line… If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1 Big Pharma’s meds to shrink your prostate are no better. These synthetic drugs have a history of nightmarish side effects. Researchers from Boston University tested the drug dutasteride — brand name Avodart — on 230 men with BPH.2   After three to four years...



Teleflex closes $1B NeoTract buy

Tue, 03 Oct 2017 13:44:25 +0100

Teleflex (NYSE:TFX) said today that it closed its $1.1 billion acquisition of NeoTract and its UroLift prostate treatment. The deal called for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughly $51 million last year, up 178% over 2015, and is expected to post sales of $115 million to $120 million this year. When the deal was announced last month, Teleflex chairman & CEO Benson Smith likened the NeoTract pickup to prior a...



Procept BioRobotics treats first patients in Water II test of surgical robot

Wed, 27 Sep 2017 16:57:09 +0100

Procept BioRobotics announced today that the first patients were treated in its Water II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia. The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients at up to 20 sites in the U.S. and Canada. Read the full story on our sister site, The Robot Report. The post Procept BioRobotics treats first patients in Water II test of surgical robot appeared first on MassDevice. (Source: Mass Device)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz

Wed, 20 Sep 2017 07:00:00 +0100

Title: Benign Prostatic Hyperplasia (Enlarged Prostate) QuizCategory: MedicineNet QuizCreated: 2/7/2012 3:29:00 PMLast Editorial Review: 9/20/2017 12:17:12 PM (Source: MedicineNet Mens Health General)



Medical News Today: Six yoga poses for prostate enlargement

Mon, 18 Sep 2017 16:00:00 +0100

Yoga has many benefits, In this article, learn about six yoga poses that can help ease and manage the symptoms of benign prostatic hyperplasia. (Source: Health News from Medical News Today)



Merit Medical licenses KatGuide pleural drain tech from Pleuratech

Fri, 15 Sep 2017 15:49:37 +0100

Merit Medical (NSDQ:MMSI) has licensed a novel surgical device designed to ensure drain placement in the pleural cavity from Pleuratech, according to a Young America Capital press release posted this week. The device is Denmark-based Pleuratech’s flagship product, the KatGuide, and is designed to guide chest tubes to the part of the pleural cavity which needs draining to reduce misplaced drains and increase surgical success rates. The companies did not release the exact terms of the deal, but said that it was a multimillion dollar license agreement, according to a press release. “As a leading manufacturer and marketer of proprietary disposable medical devices, Merit Medical Systems, Inc. is excited to add the KatGuide to our current portfolio of products.  This innovative med...



Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH

Wed, 06 Sep 2017 17:57:54 +0100

Photoselective vaporization of the prostate (PVP) offers similar efficacy with better quality of life, compared with transurethral resection of the prostate (TURP), in men with benign prostatic hyperplasia (BPH), researchers from Italy report.Reuters Health Information (Source: Medscape Medical News Headlines)



How Teleflex Bagged a $1.1 Billion Hidden Treasure

Tue, 05 Sep 2017 19:21:56 +0100

Teleflex CEO Benson Smith expected some investors to be surprised by yet another billion-dollar acquisition, but sometimes businesses simply must strike while the iron is hot. The Wayne, PA-based company said it will buy NeoTract for up to $1.1 billion. The deal comes just seven months after Teleflex completed its $1 billion acquisition of Vascular Solutions. "I'm sure that at least some of you may be a bit surprised that Teleflex is once again active in M&A so quickly after announcing the acquisition of Vascular Solutions. Well, we are not," Smith said Tuesday during a conference call. Smith said Teleflex has made significant progress with the integration of Vascular Solutions, which he attributed largely to the company's business unit structure that allows one business to integrate a...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Teleflex to pay $1.1B for NeoTract

Tue, 05 Sep 2017 11:47:04 +0100

Teleflex (NYSE:TFX) said today that it agreed to put up $1.1 billion to acquire NeoTract and its UroLift prostate treatment. The deal calls for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The deal is expected to close within 30 days. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughly $51 million last year, up 178% over 2015, and is expected to post sales of $115 million to $120 million this year. “We are excited to announce this definitive agreement with NeoTrac...



NxThera adds $6m for Rez ūm prostate device

Fri, 21 Jul 2017 11:58:46 +0100

NxThera said this week that it added another $6 million to its coffers in an ongoing round of debt financing. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the first sale logged Jan. 13. NxThera said it’s looking to raise an additional $5.8 million in the round, taking the total hoped-for raise from $15 million to $26.4 million. In Dec. 2015, Boston Scientific (NYSE:BSX) led a $40 million funding round for NxThera and its Rezūm device, saying it plans to boost its sales footprint in the U.S. and Europe. Backers Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Bridge Group also participated, NxThera said at the time. NxThera won CE Mark approval in the...



7 medtech stories we missed this week: July 7, 2017

Fri, 07 Jul 2017 17:16:26 +0100

[Image from unsplash.com]From EnvisionTEC’s FDA approval to InVivo Therapeutics adding a new clinical site, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. EnvisionTEC wins FDA nod for 3D printing E-Denture material EnvisionTEC announced in a June 30 press release that it has received FDA approval for its E-Denture material for 3D printing dentures. The company already has the E-Dent 100 and 400 materials approved for the printing of restorations that simulate teeth. The new approval makes EnvisionTEC the only 3D printing company worldwide that has a complete digital denture workflow solution. E-Denture will have a limited distribution in the third quarter and will be available in four natural shades. 2. Life Spine launches Osseo-Loc pro...



Tamsulosin and Naftopidil Offer Similar Benefits in BPH Tamsulosin and Naftopidil Offer Similar Benefits in BPH

Fri, 30 Jun 2017 18:39:51 +0100

Bladder storage symptoms associated with benign prostatic hyperplasia (BPH) improve to a similar extent with tamsulosin and naftopidil treatment, researchers from South Korea report.Reuters Health Information (Source: Medscape Medical News Headlines)



FDA grants de novo clearance for Merit Medical ’ s Embosphere

Fri, 23 Jun 2017 13:36:03 +0100

Merit Medical (NSDQ:MMSI) said yesterday that its Embosphere device won expanded de novo clearance from the  to treat benign prostatic hyperplasia. The federal safety watchdog’s clearance means Embosphere can be used in prostatic artery embolization  procedures to treat BPH. “Merit’s Embosphere is the first embolic agent to receive FDA 513(f)(2) classification for prostatic artery embolization, providing a non-surgical treatment option for millions of men who suffer from BPH,” chairman & CEO Fred Lampropoulos said in prepared remarks. The device is designed to occlude the prostatic arteries to shrink the prostate and improve BPH symptoms, South Jordan, Utah-based Merit said. The post FDA grants de novo clearance for Merit Medical’s Embosphere appeared...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Popular prostate drug linked to serious side effects

Thu, 22 Jun 2017 04:00:00 +0100

(Boston University Medical Center) Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. (Source: EurekAlert! - Medicine and Health)



2017 Eureka! Innovation award winner: NxThera Inc.

Wed, 21 Jun 2017 06:00:00 +0100

Industry category: Health Care Technology Organization size: Small — revenue less than $50 million Eureka! idea: Uses water vapor to treat endourological diseases that affect millions of men, with a safe, effective and fast procedure What the judges said:"The team is great. It's a slick treatment option — killing cells in the gentle st way possible." Benign prostatic hyperplasia, an enlargement of the prostate gland, affects 12 million men in the United States, with nearly 800,000 new diagnoses… (Source: bizjournals.com Health Care:Biotechnology headlines)



7 medtech stories we missed this week: May 26, 2017

Fri, 26 May 2017 16:08:39 +0100

[Image from unsplash.com]From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The licensing agreement is going to help with the development, manufacture and commercialization of an investigation preclinical antibody candidate that targets the protein tau. Merck will have exclusive worldwide rights to develop, manufacture and commercialize the anti-tau antibody while Teijin Pharma will receive an upfront payment for development, regulatory and sales milestone payments. Teijin Pharma ...



7 medtech stories we missed this week: May 19, 2017

Fri, 19 May 2017 19:15:42 +0100

[Image from unsplash.com]From FDA clearances to touting study data, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. XpandOrtho wins FDA 510(k) clearance XpandOrtho announced in a May 17 press release that it has received FDA 510(k) clearance for its electronic soft tissue balancing instrument for total knee replacement surgery. The sterile-packaged wireless disposable device uses miniature sensors and actuators to balance knee joints during full-range motions. Using constant pressure bellows systems, the device communicates with a display for multiaxial balance and selection of thickness and tibial component. 2. Visionsense goes after Novadaq patent Visionsense has filed an IPR with the USPTO for its Novadaq Technologies’ U.S. patent, according ...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Enlarged Prostate ( BPH, Benign Prostatic Hyperplasia)

Thu, 18 May 2017 07:00:00 +0100

Title: Enlarged Prostate ( BPH, Benign Prostatic Hyperplasia)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/18/2017 12:00:00 AM (Source: MedicineNet Mens Health General)



Enlarged Prostate (BPH, Benign Prostatic Hyperplasia)

Thu, 18 May 2017 07:00:00 +0100

Title: Enlarged Prostate (BPH, Benign Prostatic Hyperplasia)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/18/2017 12:00:00 AM (Source: MedicineNet Mens Health General)



MassDevice.com +5 | The top 5 medtech stories for May 17, 2017

Wed, 17 May 2017 19:00:44 +0100

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. 10 innovative diagnostic tests to combat diseases Medtech is seeing new exciting developments in the field of medical diagnostics, with recent innovations allowing for faster disease diagnosis than ever before. We cover 10 diagnostic tests that could change how quickly we can catch dangerous diseases. Read more   4. Robotic surgery: Here’s everything you need to know Robotic surg...



NeoTract touts 5-year UroLift study data

Tue, 16 May 2017 22:37:44 +0100

NeoTract  today presented 5-year results from the pivotal Lift IDE study of its UroLift system, touting rapid reduction of symptoms and sustained effects in treating patients with symptomatic benign prostatic hyperplasia. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. The 5-year results were presented by Dr. Claus Roehrborn of Dallas’ UT Southwestern Medical Center at the 112th annual American Urological Association meeting in Boston. Results from the trial indicated that the system and associated procedure was tolerable, and led to a rapid reduction in symptoms while preserving sexual function. The proced...



7 medtech stories we missed this week: May 12, 2017

Fri, 12 May 2017 17:34:37 +0100

[Image from unsplash.com]From Bioness’s new distribution deal to InBrace’s launch of new braces technology, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Obalon receives approval to commercialize in Middle East Obalon Therapeutics announced in a May 11 press release that it has received regulatory approvals in select Middle East markets to commercialize its 6-month, gas-filled intragastric balloon system. The FDA-approved, swallowable balloon system is designed to treat obesity and is the first and only system of its kind. The regulatory approval also accounts for its associated inflation dispenser. Obalon Therapeutics plans to fulfill an initial order for its Middle East distributor Bader Sultan during the second quarter of 2017. 2....

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




7 medtech stories we missed this week: March 31, 2017

Fri, 31 Mar 2017 20:30:41 +0100

[Image from unsplash.com]This week we saw a few FDA 510(k) clearances and one of the 1st uses of a next-generation surgical robot in Asia. Here are 7 medtech stories we missed this week but thought were still worth mentioning: 1. Corindus touts first Asian use of next-generation robot Corindus Vascular Robotics announced in a March 31 press release that robot-assisted PCI procedures were performed for the first time in Asia using the CorPath GRX system. The procedures were performed at Fu Wai Hospital. This is the first time the system has been used outside of the U.S. CorPath GRX enhances the precision and workflow of the current CorPath system and extends the capabilities and procedures that can be robot-assisted. 2. Endologix launches stent graft study Endologix has announced that the f...



Revolutionary UroLift(R) System Launches in Ireland

Thu, 23 Mar 2017 15:48:20 +0100

Innovative UroLift System to Treat Enlarged Prostate ready for roll out to Irish patients nationally PLEASANTON, California, March 23, 2017 -- (Healthcare Sales & Marketing Network) -- NeoTract, Inc., announced today that the largest private health ins... Devices, Urology, Product Launch NeoTract, UroLift, Benign Prostatic Hyperplasia (Source: HSMN NewsFeed)



NxThera raises $15 million

Fri, 03 Mar 2017 22:41:51 +0100

NxThera  has raised $14.6 million in a new round of debt financing, according to an SEC filing posted this week. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the 1st sale noted on Jan. 13. NxThera is looking to raise an additional $809,831 in the round, and noted on the SEC filing that the amount sold does not include foreign purchasers. The company has not yet stated how it plans to spend funds raised in the round. In Dec. 2015, NxThera said that Boston Scientific (NYSE:BSX) led a $40 million funding round for its Rezūm device, saying it plans to boost its sales footprint in the U.S. and Europe. Backers Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Br...



What Every Man Must Know About BPH

Tue, 28 Feb 2017 17:46:08 +0100

One of the most common conditions a man can get affecting his prostate is benign prostatic hyperplasia or BPH. BPH is an enlargement of the prostate putting pressure on the urethra making it difficult to urinate along with other symptoms associated with it. It becomes more prevalent as a man ages with the risk of BPH increasing each year after a man turns 40. By age 60, more than half of all men will have BPH and by age 85, about 90 percent of men have this condition. How will a man know if he has BPH? Most of the signs and symptoms of BPH are urinary related. The prostate gland, the size of a walnut, surrounds the urethra the tube in which urine is released through. As the prostate enlarges, this put pressure on the urethra reducing the flow of urine which can result in various symptoms s...



NxThera raises $12.2m

Fri, 03 Feb 2017 21:30:37 +0100

NxThera raised $12.2 million in a new round of financing, according to an SEC filing posted this week. Funds in the round come through the offering of debt, warrants, convertible promissory notes and Series C preferred stock warrants, according to the filing. Funds in the round were raised by 28 unnamed US purchasers, according to the SEC filing, and the company has not yet stated how it plans to use funds raised. Last December, NxThera said that Boston Scientific (NYSE:BSX) led a $40 million funding round for its Rezūm device, saying it plans to boost its sales footprint in the U.S. and Europe. Existing backers Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Bridge Group also participated, Maple Grove, Minn.-based NxThera said. NxThera won CE Mark approval in the E...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Guidelines for the Treatment of Benign Prostatic Hyperplasia Guidelines for the Treatment of Benign Prostatic Hyperplasia

Fri, 03 Feb 2017 11:29:33 +0100

This article presents an overview of the many therapeutic options for benign prostatic hyperplasia, including lifestyle modifications, pharmacotherapy, and surgical interventions.U.S. Pharmacist (Source: Medscape Today Headlines)



Dr. David Samadi Explains Why Enlargement Of The Prostate Is More...

Tue, 24 Jan 2017 10:23:05 +0100

Dr. David Samadi gives his opinion on a recent retrospective cohort study out of Korea on findings showing benign prostatic hyperplasia is more likely to develop in men having a high body mass index...(PRWeb January 24, 2017)Read the full story at http://www.prweb.com/releases/David_Samadi/BPH/prweb14004896.htm (Source: PRWeb: Medical Pharmaceuticals)



Medical News Today: Benign Prostatic Hyperplasia: Treatment, Symptoms, and Causes

Wed, 04 Jan 2017 08:00:00 +0100

What is BPH and what are the causes and risk factors? Learn about its diagnosis, complications, medication that may be used, and tips for living with BPH. (Source: Health News from Medical News Today)



unctional Autoantibodies May Promote BPH unctional Autoantibodies May Promote BPH

Fri, 16 Dec 2016 01:16:09 +0100

Overstimulation by autoantibodies targeting the endothelin A receptor (ETA-AABs) may play a role in the development of benign prostatic hyperplasia (BPH), new research suggests.Reuters Health Information (Source: Medscape Pathology Headlines)



Functional Autoantibodies May Promote BPH Functional Autoantibodies May Promote BPH

Fri, 16 Dec 2016 01:16:09 +0100

Overstimulation by autoantibodies targeting the endothelin A receptor (ETA-AABs) may play a role in the development of benign prostatic hyperplasia (BPH), new research suggests.Reuters Health Information (Source: Medscape Pathology Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Prostatic Urethral Lift Relieves BPH Symptoms Prostatic Urethral Lift Relieves BPH Symptoms

Tue, 29 Nov 2016 20:28:46 +0100

The prosthetic urethral lift (PUL) procedure relieves lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), researchers report.Reuters Health Information (Source: Medscape General Surgery Headlines)



Neotract touts coverage win for UroLift prostate device

Tue, 15 Nov 2016 19:20:12 +0100

NeoTract said today it won coverage for its Urolift system from Medicare Administrative Contractor First Coast Service Options. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. First Coast Service Options covers Florida, Puerto Rico and the U.S. Virgin Islands, the Pleasanton, Calif.-based company said. “We are thrilled that millions of men across the United States now have access to the UroLift System treatment. The recently published four-year clinical data showing the durable benefits of the UroLift System, in addition to the procedure’s already-established uniquely rapid relief, have compelled Medicare ...



Benign Prostatic Hyperplasia (BPH) Treatment Should Be Individualized...

Tue, 04 Oct 2016 10:07:02 +0100

BPH affects approximately 50% of men between the ages of 51 - 60 & up to 90% of men over the age of 80. Men need to work with their doctor to determine which treatment option is right for them.(PRWeb October 04, 2016)Read the full story at http://www.prweb.com/releases/BPH_Enlarged_Prostate/David_Samadi/prweb13732813.htm (Source: PRWeb: Medical Pharmaceuticals)



NeoTract touts reimbursement win for UroLift

Mon, 03 Oct 2016 19:28:24 +0100

NeoTract today touted a reimbursement win from Geisinger Health Plan and EmblemHealth that will allow coverage for procedures using its UroLift system for patients with benign prostatic hyperplasia. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. Geisinger Health Plan serves 540,000 members in Pennsylvania, New Jersey, Delaware, Main and West Virginia, while EmblemHealth serves New York, New Jersey and Connecticut. “We are pleased to see the continued expansion of access to UroLift for millions of men across the United States who are seeking this much less invasive treatment for BPH. That integrated healthca...



BPH Drugs Don't Independently Raise the Risk of ED: Study BPH Drugs Don't Independently Raise the Risk of ED: Study

Thu, 29 Sep 2016 20:04:04 +0100

A large observational study finds no evidence that use of 5-alpha-reductase inhibitors for benign prostatic hyperplasia (BPH) or alopecia raise the risk of erectile dysfunction.Reuters Health Information (Source: Medscape Urology Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




National Prostate Cancer Awareness Month -- Educating All Men On Reducing Their Risk

Fri, 23 Sep 2016 19:30:15 +0100

This study only looked at the effect of dietary or food sources of zinc and not at zinc supplements. Some dietary sources of zinc include the following: • Beef steak - 3 oz contains 4.9 mg • Oysters - 3 oz contains 67 mg • Shrimp - 3 oz contains 1.5 mg • Pork chop - 3 oz contains 2.8 mg • Yogurt - 1 cup contains 2.2 mg • Enriched cereal - ¾ cup contains 15 mg • Red kidney beans - ½ cup contains 2 mg Zinc coming from meat sources is more readily bioavailable than zinc from vegetarian sources. Legumes and whole grains contain phytic acid inhibiting zinc's bioavailability. Consult with your doctor for their recommendation on whether to supplement with zinc or not. The 2011 Swedish cohort study suggested that their results were not sufficient to recommend zinc supplements. In...



Finasteride, Dutasteride Don't Seem to Increase Risk for Erectile Dysfunction (FREE)

Thu, 22 Sep 2016 22:00:00 +0100

By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS The 5-alpha reductase inhibitors finasteride and dutasteride do not appear to increase risk for erectile dysfunction in men with benign prostatic hyperplasia … (Source: Physician's First Watch current issue)



Ultrasound Noninvasively Detects Bladder Outlet Obstruction Ultrasound Noninvasively Detects Bladder Outlet Obstruction

Wed, 21 Sep 2016 19:17:09 +0100

Bladder and prostate ultrasonography noninvasively detects bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia (BPH), researchers from Saudi Arabia report.Reuters Health Information (Source: Medscape Radiology Headlines)



Audax deals Laborie Medical to Patricia Industries

Mon, 19 Sep 2016 17:39:05 +0100

Private equity player Audax Group said today it sold Laborie Medical Technologies to Investor AB subsidiary Patricia Industries for an undisclosed amount. Toronto-based Laborie Medical Tech develops and manufactures urological, pelvic health and gastrointestinal medical devices used for diagnosis and treatment of urinary incontinence and other urological and GI conditions, Audax Medical said. Laborie acquired the pelvic muscle rehabilitation business of UroMed Technology in October 2013 for an undisclosed amount. “Under Audax’ ownership, Laborie transformed from a manufacturer of capital equipment for urodynamic testing into a fully-integrated medical device company with a market-leading position in urology and a rapidly growing gastroenterology business. We are proud of the sha...



Enlarged prostate: Mayo Clinic Radio Health Minute

Thu, 15 Sep 2016 22:00:00 +0100

In this Mayo Clinic Radio Health Minute, we hear from Dr. Amy Krambeck about enlarged prostates, a condition know as benign prostatic hyperplasia.. To listen, click the link below. Enlarged Prostate (Source: News from Mayo Clinic)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Medical News Today: Enlarged prostate: Molecular mechanism clue may explain link to inflammation

Tue, 06 Sep 2016 14:00:00 +0100

Discovery of molecular mechanism may explain how inflammation leads to benign prostatic hyperplasia and improve response to androgen-targeted therapies. (Source: Health News from Medical News Today)



Serendipitous finding leads scientists to propose mechanism to explain benign prostatic hyperplasia

Thu, 01 Sep 2016 16:48:28 +0100

Benign prostatic hyperplasia affects about half of men between 51 and 60 years of age, and nine out of 10 men older than 80. How BPH happens, however, is still open for debate. A new report outlines a new mechanism that can explain the development of BPH and suggest strategies to improve the response to androgen-targeting therapies. (Source: ScienceDaily Headlines)



Button TURP vs. Green Light Laser for Benign Prostatic Hyperplasia -...

Wed, 10 Aug 2016 12:17:01 +0100

Button TURP and Green Light Laser are less invasive prostate surgeries used to treat BPH, a condition that affects 50% of men in their 50s and as many as 90% by the time a man reaches his 70s, or...(PRWeb August 10, 2016)Read the full story at http://www.prweb.com/releases/Dr_David_Samadi/BPH/prweb13605293.htm (Source: PRWeb: Medical Pharmaceuticals)



Many Commonly Used Drugs Are Useless

Sun, 07 Aug 2016 23:01:57 +0100

Some medications are life saving. I am so thankful for the trusty med that tames my atrial fibrillation. Many meds are helpful -- demonstrating superiority to placebo in ways that are clearly clinically significant and life enhancing. But many (perhaps most) drugs are probably no more than very expensive placebos. Patients get prescriptions from doctors when their symptoms are most severe and improve with time and positive expectation, not because the med is really effective. Doctors and patients need independent, objective information on drug efficacy and risks. The multibillion dollar pharma marketing machine can turn even the most useless and harmful drugs into financial blockbusters. Doctors and patients need independent, objective information on drug efficacy and risks. This is...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Medi-Tate wins strategic investment from Canada’s Laborie Medical Technologies

Thu, 07 Jul 2016 16:38:32 +0100

Laborie Medical Technologies said it took out a stake in Israel’s Medi-Tate, which is developing devices to treat enlarged prostates, for an unspecified amount. Toronto-based Laborie, which is owned by private equity company Audax Group, in October 2013 acquired the pelvic muscle rehabilitation business of UroMed Technology, also for an undisclosed amount. Akiva, Israel-based Medi-Tate developed a minimally invasive treatment for benign prostate hyperplasia called iTind, which uses a 5-day implant to reshape the urethra and create new channels for urine flow. It’s designed to lower the risk of post-procedural sexual dysfunction associated with pharmaceutical or surgical treatments, Laborie said. “We are very pleased to be partnering with Laborie. By combining our i...



NeoTract logs reimbursement wins for UroLift prostate treatment

Thu, 07 Jul 2016 16:18:58 +0100

NeoTract said today that it logged several reimbursement wins for its UroLift treatment for enlarged prostates, including a Medicare contractor and at least 7 independent insurers. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. Today NeoTract said Medicare contractor National Government Services agreed to cover UroLift patients in Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin. Private insurers Kaiser Permanente, SelectHealth and Blue Cross Blue Shield plans including CareFirst, Highmark, Louisiana, Nebraska and South Carolina also added c...



UroLift Device Useful, But Likely Not a Game-Changer for Treating BPHUroLift Device Useful, But Likely Not a Game-Changer for Treating BPH

Wed, 29 Jun 2016 20:05:26 +0100

Placement of the UroLift device provides durable relief of benign prostatic hyperplasia (BPH) symptoms at 12 months and leads to improvements in both subjective and objective outcome measures, according to a recent systematic review of research on this treatment. Reuters Health Information (Source: Medscape Medical News Headlines)



MassDevice.com +5 | The top 5 medtech stories for June 16, 2016

Thu, 16 Jun 2016 19:00:17 +0100

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Si-Bone touts updated 510(k) clearance indications, MAC reimbursement wins for iFuse Si-Bone said this week it won updated 510(k) clearance indications for its iFuse implant system and reimbursement coverage for its minimally invasive surgery sacroiliac joint fusion systems through Medicare Administrative Contractor FCSO. Si-Bone said the FDA modified the indication statement for its iFuse sacro...



Benign Prostatic Hyperplasia and Complementary and Integrative Approaches

Thu, 16 Jun 2016 17:28:07 +0100

Research results on complementary and integrative health approaches benign prostatic hyperplasia, including acupuncture, lycopene, Pygeum africanum, saw palmetto, and urtica dioica. For health care providers. (Source: NCCAM Featured Content)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Boston Scientific wins UK NICE support for GreenLight laser therapy

Thu, 16 Jun 2016 14:50:55 +0100

Boston Scientific (NYSE:BSX) said Tuesday that the U.K.’s National Institute for Health and Care Excellence now provides guidance supporting the use of its GreenLight XPS laser therapy system used to treat prostatic enlargement in patients with benign prostatic hyperplasia. NICE, which provides evidence-based guidance and standards to the U.K.’s National Health Service, said that adoption of the GreenLight XPS system to treat non high-risk patients with BPH can “significantly reduce costs for the NHS,” Marlborough, Mass.-based Boston Scientific said. “The GreenLight XPS System is a well-established treatment to help men with BPH. It is suitable for almost all men, even those who may not be deemed fit for conventional surgery. The positive guidance from NICE w...



Benign Prostatic Hyperplasia and Complementary and Integrative Approaches

Wed, 15 Jun 2016 16:32:18 +0100

Research results on complementary and integrative health approaches benign prostatic hyperplasia, including acupuncture, lycopene, Pygeum africanum, saw palmetto, and urtica dioica. For health care providers. (Source: NCCAM Featured Content)



NeoTract touts 4-year UroLift data

Mon, 09 May 2016 22:38:06 +0100

NeoTract today released the results from 2 randomized studies of its UroLift system designed to treat benign prostatic hyperplasia, touting “excellent” durability after 4 years. The data was presented at the American Urological Association’s 2016 annual meeting in San Diego this week. “The clinical data presented at this year’s AUA conference show that treatment with the UroLift System offered men suffering from BPH a well-tolerated minimally invasive experience that provided uniquely rapid relief and a durable, sustained effect. We are proud to offer this safe and effective treatment option that can allow men to stop taking BPH medications and be treated with a simple procedure that does not carry the risk of sexual side effects common with other treatment optio...



Urologix successor details dissolution plans

Mon, 25 Apr 2016 20:45:26 +0100

The successor to Urologix said today that it plans to completely dissolve during 2017, spelling the end for the Minneapolis-based urology device maker. Urologix, which made the Cooled ThermoTherapy and Prostiva RF devices to treat benign prostatic hyperplasia, licensed Prostiva from Medtronic (NYSE:MDT). But after running up a $2.8 million tab on its Twin Cities neighbor, Urologix couldn’t come up with the payments. Its assets were put up as collateral on the debt, which defaulted April 14, 2015, leading to their sale to a secured creditor, which inturn sold them to a private company that plans to run the business under the Urologix banner. Today the successor company, 21st North, said it failed more than once to raise a quorum of shareholders to vote on dissolving the compa...



NOS Pathway Linked to Treatment Response in Men With BPHNOS Pathway Linked to Treatment Response in Men With BPH

Fri, 25 Mar 2016 18:52:47 +0100

The eNOS G894T polymorphism is associated with reduced responsiveness to alpha-1 blocker treatment in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), researchers from Taiwan have reported. Reuters Health Information (Source: Medscape Medical News Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Less Invasive Prostatic Lift Beats Transurethral ResectionLess Invasive Prostatic Lift Beats Transurethral Resection

Mon, 21 Mar 2016 20:19:25 +0100

There are pros and cons of prostatic urethral lift for men with urinary symptoms related to benign prostatic hyperplasia, but patient-centered outcomes favor the lift over traditional treatment. Medscape Medical News (Source: Medscape Medical News Headlines)



The European Association of Urology Upgrades UroLift(R) System Trial Data to its Highest Possible Classification - Level 1A - in its Guidelines

Mon, 14 Mar 2016 13:31:51 +0100

Further evidence from two multi-national randomized studies presented at EAU conference supports durability of UroLift® System treatment for men with enlarged prostate MUNICH, March 14, 2016 -- (Healthcare Sales & Marketing Network) -- The UroLift ... Devices, UrologyNeoTract, UroLift, Benign Prostatic Hyperplasia (Source: HSMN NewsFeed)



NeoTract launches MedLift trial

Fri, 11 Mar 2016 22:45:45 +0100

NeoTract said Monday it enrolled the 1st patient in its MedLift U.S. investigational device exemption trial of its UroLift system for treating patients with benign prostatic hyperplasia. The new study from Pleasanton, Calif.-based NeoTract will be conducted across 8 sites in the U.S. and will examine the safety and efficacy of the UroLift system for treating patients with BPH who have an obstructive median lobe, which the company says is currently contraindicated in the U.S. “Unlike other BPH procedures, the UroLift System directly opens the urethra without cutting, heating, or removing prostate tissue. In this way patients experience very rapid and durable relief. This treatment option has been very successful for many of my BPH patients who are unhappy with medical therapy and conc...



Learn More About TURP Procedure for Prostate...

Sun, 07 Feb 2016 00:00:00 +0100

The TURP (transurethral resection of the prostate) procedure commonly used to treat benign prostatic hyperplasia (BPH) can also be used in men with prostate cancer. (Source: About.com Prostate Cancer)



Learn More About Benign Prostatic Hyperplasia

Sat, 06 Feb 2016 00:00:00 +0100

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate that can cause urinary symptoms identical to prostate cancer. (Source: About.com Prostate Cancer)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




MassDevice.com +3 | The top 3 medtech stories for February 3, 2016

Wed, 03 Feb 2016 20:00:24 +0100

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Johnson & Johnson escapes DePuy Pinnacle hip implant lawsuit Johnson & Johnson subsidiary DePuy Orthopaedics won the dismissal of a False Claims Act lawsuit brought by a pair of British surgeons over its since-recalled Pinnacle metal-on-metal hip implant. Drs. Antoni Nargol and David Langton sued in 2012, alleging that DePuy Orthopaedics committed fraud when it billed federal agencies for Pinnacle implantation procedures, because it knew of and conceal...



Urologix sold to settle debt to Medtronic

Wed, 03 Feb 2016 13:03:02 +0100

Urologix Inc. (OCT:ULGX) yesterday said almost all of its assets to a secured creditor, which then sold them to a private company that will operate the business as Urologix LLC. The remnants of Urologix Inc. were renamed 21st North Inc. The Minneapolis-based company, which makes the Cooled ThermoTherapy and Prostiva RF devices to treat benign prostatic hyperplasia, licensed Prostiva from Medtronic (NYSE:MDT). As of March 31, 2015, Urologix owed its Twin Cities neighbor some $2.8 million, according to a regulatory filing, and lacked the scratch to pay up. All of its assets, including intellectual property, were put up as collateral to Medtronic, according to the filing. The nut consisted of a $1.3 million payment due on a $5.3 million promissory note and $1.5 million in royalties and ot...



Men with severe lower urinary tract symptoms are at increased risk of depression - Jeong WS, Choi HY, Nam JW, Kim SA, Choi BY, Moon HS, Kim KS.

Mon, 18 Jan 2016 21:15:44 +0100

PURPOSE: Lower urinary tract symptoms (LUTS) comprise a set of common, bothersome symptoms in middle-aged and elderly men. Recent research suggests that depressive symptoms may influence the symptoms of benign prostatic hyperplasia (BPH). We performed a co... (Source: SafetyLit)



MassDevice.com +3 | The top 3 medtech stories for November 5, 2015

Thu, 05 Nov 2015 20:00:26 +0100

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Gauss Surgical wins CE Mark for Triton blood loss monitor Gauss Surgical said it won CE Mark approval in the European Union for its Triton mobile real-time surgical blood loss monitoring system. The device works with Apple’s iPad system and is the 1st and only mobile platform for surgical blood loss monitoring, the Los Altos, Calif.-based company said. Read more 2. Boston Scientific, Edwards facing off in new TAVR battle A new patent spat is bein...



Hansen touts 1st clinical use of robotic Magellan microcath driver

Wed, 04 Nov 2015 20:46:59 +0100

Hansen Medical (NSDQ:HNSN) said today its Magellan microcatheter driver has been used in its 1st clinical procedure, performing an embolization in the peripheral vasculature to treat a benign prostatic hyperplasia. The procedure was performed in Paris at the Hôpital Européen Georges Pompidou by device clinical study principal investigator Dr. Marc Sapoval and Dr. Gregory Amouyal, the Mountain View, Calif.-based company said. “We are pleased to complete the world’s 1st clinical procedure using the Magellan Microcatheter Driver as part of this clinical study. Manual control of microcatheters and microwires can be challenging, particularly in tortuous anatomy. By utilizing the Microcatheter Driver in conjunction with the Magellan 6Fr Robotic Catheter, we are enhancing the util...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Nigeria: Regular Sex, Exercise Minimise Prostrate Cancer

Mon, 19 Oct 2015 14:45:56 +0100

[This Day] A pharmacist at the University of Ilorin Teaching Hospital (UITH), Mr. Lanre Alege, has called for lifestyle changes to minimise the risk of Benign Prostate Hyperplasia (BPH). (Source: AllAfrica News: Health and Medicine)



Nigeria: Regular Sex, Exercise, Minimise BPH - Pharmacist

Sun, 18 Oct 2015 19:28:08 +0100

[Vanguard] Mr Lanre Alege, a Pharmacist at the University of Ilorin Teaching Hospital (UITH), on Sunday called for lifestyle changes to minimise the risk of Benign Prostate Hyperplasia (BPH). (Source: AllAfrica News: Health and Medicine)



The cruel problem most men are too embarrassed to mention: A distinguished author writes with searing honesty about incontinence after prostate surgery

Mon, 12 Oct 2015 22:52:15 +0100

'I was suffering from benign prostatic hyperplasia or BPH, a condition affecting 30 per cent of men over 50', writes PHILIP NORMAN. (Source: the Mail online | Health)



Teva Announces Exclusive Launch of Generic Avodart(R) Capsules in the United States

Mon, 12 Oct 2015 18:10:43 +0100

JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd., (TEVA) today announced the exclusive launch of the generic equivalent to Avodart® (dutasteride) capsules, 0.5 mg, in the United States. Dutasteride is a 5 alpha-red... Biopharmaceuticals, Urology, Generics, Product LaunchTeva Pharmaceutical, Avodart, dutasteride, benign prostatic hyperplasia (Source: HSMN NewsFeed)



Neotract touts UK NHS savings, better reimbursements

Thu, 17 Sep 2015 17:41:38 +0100

Neotract said today a new analysis from the U.K.’s National Institute for Health and Care Excellence reported a (UK £286) $443 savings per patient per day when using its UroLift system to treat enlarged prostates, compared to the most common surgical intervention. The NICE reported other benefits of the system, including preservation of sexual function, improved quality of life and reduced recovery time with the treatment, compared to the standard treatment, Pleasanton, Calif.-based Neotract said. “The NICE report dovetails well with an analysis we published December 2013 in Population Health Management that showed an anticipated 30% savings of UroLift versus standard surgery, based on a two year horizon of care within the US Medicare system,” Jefferson College of Popu...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Procept BioRobotics closes $42m round for AquaBeam prostate device

Tue, 07 Jul 2015 13:48:24 +0100

Procept BioRobotics said today that it closed on a $42 million round for its AquaBeam “waterjet ablation” device for treating prostate cancer. Redwood Shores, Calif.-based Procept said the round was led by Novo Nordisk’s (NYSE:NVO) investment arm, Novo A/S, with new backer CPMG and existing investors also contributing. The AquaBeam device uses a high-pressure water jet to excise tissue from the prostate. The jet’s pressure is then reduced so that is can be used to carry a laser light beam to cauterize the incision. The aim is to reduce the heat damage to adjacent tissue common in more standard interventions. The system uses image-based ultrasound to help surgeons map, plan and execute the procedure. Procept said it plans to use the proceeds to back a limited com...



The Miriam Hospital now offering new innovative prostate treatment

Mon, 22 Jun 2015 04:00:00 +0100

(Lifespan) The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia, an enlarged prostate condition. (Source: EurekAlert! - Medicine and Health)



Implementing decision aids affects care decisions in urology

Mon, 23 Mar 2015 04:00:00 +0100

(Group Health Research Institute) After Group Health Cooperative implemented video-based decision aids for men with two common prostate conditions, rates of elective surgery for benign prostatic hyperplasia and rates of active treatment for localized prostate cancer declined over six months. But the total cost of health care for those patients did not fall significantly. (Source: EurekAlert! - Medicine and Health)



New Procedure Alternative to Surgery for Enlarged ProstateNew Procedure Alternative to Surgery for Enlarged Prostate

Fri, 13 Mar 2015 00:15:50 +0100

For men with benign prostatic hyperplasia, artery embolization provides excellent control of lower urinary tract symptoms, report investigators pioneering the new approach. Medscape Medical News (Source: Medscape Urology Headlines)



UCLA researchers discover 400% variation in cost of treatments for enlarged prostate

Thu, 12 Mar 2015 15:27:00 +0100

Courtesy of Alan Kaplan Dr. Alan Kaplan UCLA researchers found a 400 percent discrepancy between the least and most expensive ways to treat a common condition called benign prostate hyperplasia. Their study was the first to describe cost across the entire care process for the condition. Dr. Alan Kaplan, the study’s first author and a resident physician in the UCLA department of urology, said the finding is important because there isn’t any proven difference in outcomes between the lower- and higher-cost treatments. The study appears in the March issue of Healthcare: The Journal of Delivery Science and Innovation. During the year-long study, conducted at the UCLA Ronald Reagan Medical Center, the researchers used a technique called time-driven activity-based costing to determine how mu...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




UCLA researchers for the first time measure the cost of care for a common prostate condition

Tue, 10 Mar 2015 04:00:00 +0100

(University of California - Los Angeles Health Sciences) UCLA researchers have for the first time described cost across an entire care process for a common condition called benign prostate hyperplasia using time-driven activity-based costing. They found a 400 percent discrepancy between the least and most expensive ways to treat the condition. (Source: EurekAlert! - Medicine and Health)



SIR: Study backs embolization for BPH

Mon, 02 Mar 2015 21:25:02 +0100

Clinicians improved the symptoms of men with benign prostatic hyperplasia (BPH) (more) (Source: AuntMinnie.com Headlines)



Prostatic Urethral Lift an Option to Ease BPH SymptomsProstatic Urethral Lift an Option to Ease BPH Symptoms

Mon, 01 Dec 2014 21:28:36 +0100

The prostatic urethral lift (PUL) procedure improves urinary symptoms and flow while preserving sexual function in men with benign prostatic hyperplasia (BPH), according to a meta-analytic review by researchers from Australia. Reuters Health Information (Source: Medscape Medical News Headlines)



NeoTract wins Medicare coverage for prostate treatment

Tue, 11 Nov 2014 13:32:17 +0100

NeoTract says the U.S. Centers for Medicare and Medicaid Services (CMS) has okayed reimbursement for the company's UroLift System for the treatment of benign prostatic hyperplasia (BPH), or enlarged prostate. NeoTract said the Centers for Medicare & Medicaid Services OK'd reimbursement for its UroLift system for treating benign prostatic hyperplasia, or enlarged prostate. Coverage for the product is slated to begin Jan. 1, 2015. Centers for Medicare and Medicaid Services (CMS), NeoTractNews Well, Reimbursement, Urologyread more (Source: Mass Device)



How closely do urologists adhere to AUA guidelines?

Wed, 15 Oct 2014 04:00:00 +0100

(Elsevier Health Sciences) Evidence-based guidelines play an increasing role in setting standards for medical practice and quality but are seldom systematically evaluated in the practice setting. Investigators evaluated the rate of physician adherence to the American Urological Association's guidelines on the management of benign prostatic hyperplasia/lower urinary tract symptoms to establish a benchmark for future research. Their findings are published in The Journal of Urology. (Source: EurekAlert! - Medicine and Health)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Nonsurgical treatment for enlarged prostate on the horizon

Mon, 23 Jun 2014 04:00:00 +0100

(Parsemus Foundation) A study published in The Prostate offers hope to men suffering from benign prostatic hyperplasia. Scientists treated 20 affected dogs with pulsed electromagnetic field therapy for 5 minutes, twice a day, for three weeks. This noninvasive technique resulted in an average 57 percent decrease in the size of the prostate gland. The researchers also found no side effects or impact on libido, semen quality, or testosterone levels. This treatment may prove useful for human BPH. (Source: EurekAlert! - Social and Behavioral Science)



Mount Sinai presents important findings at the 2014 American Urological Association Meeting

Sat, 17 May 2014 04:00:00 +0100

(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at the Icahn School of Medicine at Mount Sinai will present several landmark studies at the 2014 American Urological Association annual meeting May 17-19, 2014, in Orlando, Fla., including data on an immune response in prostate cancer tumors, effects of paternal age on stimulated insemination live birth rates, issues of sexual function after cystectomy and a comparison of modalities for the treatment of benign prostatic hyperplasia. (Source: EurekAlert! - Medicine and Health)



Electronic nose sniffs out prostate cancer using urine samples

Thu, 01 May 2014 20:56:19 +0100

We may soon be able to make easy and early diagnoses of prostate cancer by smell. Investigators have established that a novel noninvasive technique can detect prostate cancer using an electronic nose. In a proof of principle study, the eNose successfully discriminated between prostate cancer and benign prostatic hyperplasia (BPH) by "sniffing" urine headspace (the space directly above the urine sample). Results using the eNose are comparable to testing prostate specific antigen (PSA). (Source: ScienceDaily Headlines)



Featured in NEJM Journal Watch: Tadalafil Might Ease Symptoms of Benign Prostatic Hyperplasia (FREE)

Wed, 16 Apr 2014 00:00:00 +0100

By the NEJM Journal Watch Editors In an analysis … (Source: Physician's First Watch current issue)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Clinical Trial Confirms Benign Prostatic Hyperplasia and Chronic...

Wed, 26 Mar 2014 23:25:07 +0100

Over 200 men with benign prostatic hyperplasia (BPH) and chronic prostatitis have been taking part in a clinical trial of Dr Allen’s Device at the Department of Urology at The Mikaelyan Institute of...(PRWeb March 26, 2014)Read the full story at http://www.prweb.com/releases/bph_prostatitis_treatment/drallensdevice_med-trial/prweb11696214.htm (Source: PRWeb: Medical Pharmaceuticals)



BPH Treatment with Dr. Allen’s Device Shrinks Enlarged Prostate...

Fri, 21 Mar 2014 23:05:04 +0100

Preliminary results of clinical studies of men with benign prostatic hyperplasia (BPH) conducted at the Department of Urology at The Mikaelian Institute of Surgery have shown that enlarged prostate...(PRWeb March 21, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11693172.htm (Source: PRWeb: Medical Pharmaceuticals)



NxThera closes $20M Series C round

Tue, 04 Mar 2014 13:59:30 +0100

NxThera puts a bow on a $20 million Series C round for its Rezūm prostate device. NxThera said it closed a $20 million Series C round that topped its initial $18 million target. Maple Grove, Minn.-based NxThera won CE Mark approval in the European Union last August for its Rezūm prostate device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia. NxThera Inc.News Well, Funding Roundup, Prostateread more (Source: Mass Device)



Alfuzosin for BPH Linked to Fewer Snags in Cataract SurgeryAlfuzosin for BPH Linked to Fewer Snags in Cataract Surgery

Fri, 14 Feb 2014 09:20:56 +0100

Alfuzosin for benign prostatic hyperplasia causes fewer cataract surgery complications than tamsulosin. Medscape Medical News (Source: Medscape Ophthalmology Headlines)



HoLEP effective for overactive bladder symptoms

Mon, 13 Jan 2014 05:35:46 +0100

Research shows that Holmium laser enucleation of the prostate is effective in improving overactive bladder symptoms and urodynamic parameters in men with benign prostatic hyperplasia. (Source: MedWire News - Urology)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Benign Prostatic Hyperplasia

Wed, 11 Dec 2013 07:00:00 +0100

Title: Benign Prostatic HyperplasiaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/11/2013 12:00:00 AM (Source: MedicineNet Mens Health General)



Sperm blocking study brings 'male pill' closer

Tue, 03 Dec 2013 10:30:00 +0100

Conclusion This laboratory study has investigated the effects on male fertility of a blocked ejaculation process following the depletion of two genes in a group of genetically modified mice. As the researchers say, there is a need for different approaches to male contraception because most strategies have so far focused on hormonal approaches that produce dysfunctional sperm. The researchers say these often have intolerable side effects, such as affecting male sexual activity or causing long-term irreversible effects on infertility. This laboratory study demonstrated that 100% male infertility was achieved among a group of genetically modified mice, with no negative effects on sexual behaviours or sperm function. The researchers say the same effects could be achieved using oral drugs. T...



Male contraceptive pill 'a step closer'

Mon, 02 Dec 2013 21:19:34 +0100

Researchers announce discovery of proteins that can be blocked to prevent the launch of sperm cells during ejaculationA pill that provides a safe, effective and reversible method of contraception for men has been brought a step closer by scientists.Researchers identified two proteins that can be blocked to prevent the launch of sperm cells from the testes during ejaculation. Knocking out the proteins in genetically engineered mice resulted in male animals that were completely infertile, though they continued to mate normally. A similar goal could theoretically be achieved by suppressing the proteins with drugs, scientists say. In fact, medicines for prostate enlargement and high blood pressure already exist that blocks one of them."This concept is indeed a feasible mechanism of producing m...



Risk of Severe Hypotension in Men Treated With TamsulosinRisk of Severe Hypotension in Men Treated With Tamsulosin

Fri, 29 Nov 2013 17:00:00 +0100

Especially after starting or restarting treatment for benign prostatic hyperplasia, tamsulosin appears to be associated with an increased risk of severe hypotension. Reuters Health Information (Source: Medscape Medical News Headlines)



Watchful waiting can do the job of BPH medications for some men

Sun, 03 Nov 2013 05:15:25 +0100

Many men over 50 take a daily medication to control bothersome urinary symptoms of benign prostatic hyperplasia (BPH). Yet there's an alternative called watchful waiting for men with mild to moderate BPH symptoms, reports the November 2013 Harvard Men's Health Watch. It basically means making lifestyle changes and monitoring symptoms closely until medication or other action is really necessary. BPH, caused by an overgrown prostate gland, triggers a variety of problems, including frequent urination at night, difficulty completely emptying the bladder, and the urgent need to urinate at inconvenient times. "Watchful waiting is broadly available to men who have lower urinary tract symptoms attributed to BPH, but who are not bothered enough to take on the small but finite risks of treatment, su...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Sophiris starts dosing patients in Phase III study of prostate drug

Tue, 29 Oct 2013 00:00:00 +0100

Canadian urology firm Sophiris Bio has dosed the first patient in a Phase III trial of PRX302 (topsalysin) for the treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH or enlarged prostate). (Source: Drug Development Technology)



What Is BPH, or an Enlarged Prostate?

Sat, 12 Oct 2013 04:00:00 +0100

Benign prostatic hyperplasia (BPH), or "enlarged prostate," is a condition that can cause many of the (Source: About.com Prostate Cancer)